Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoldonrasib plus Daraxonrasib vs Chemotherapy in First-Line Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
NCT07805954Phase 3Recruiting
- Sponsor
- Revolution Medicines
- Start
- Aug 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
A Phase 3 trial of zoldonrasib, daraxonrasib in pancreatic adenocarcinoma (PDAC), sponsored by Revolution Medicines. Started Aug 2026; status: recruiting.
02
Drugs
zoldonrasibdaraxonrasib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07805954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07805954.